PropThink: ArQule Rising on SPA Agreement with FDA, Further Indications for tivantinib

[ACN Newswire] – By Jake KingShares of ArQule (NASDAQ:ARQL) are up 8% on news that the FDA has agreed to a Special Protocol Assessment for the company’s planned Phase III tivantinib trial. ArQule is designing a study of … more

View todays social media effects on ARQL

View the latest stocks trending across Twitter. Click to view dashboard